ICNApedia - Platform Presentations

Loading data...

Platform	Section	Title	Presenter	City	Country
PL001	Brain Tumors/Oncology	Biomarkers of CAR T cell neurotoxicity: CSF NFL and GFAP in an expansion cohort of pediatric ALL patients	Juliane Gust	Seattle	United States
PL002	Brain Tumors/Oncology	Impact of Molecular Subgrouping on Event-Free Survival (EFS): Results of a Children’s Oncology Group (COG) Randomized Trial for Children with Medulloblastoma (MB); COG-ACNS 0331	Roger Packer	Washington	United States
PL003	Cognitive/Behavioral Disorders (including Autism)	Clinical profile of children presenting with functional neurological complaints from a tertiary care center in north India	Sheffali Gulati	New Delhi	India
PL004	Cognitive/Behavioral Disorders (including Autism)	Increased Autoimmune Disease in Mothers of Children with Tourette Syndrome and Obsessive-Compulsive Disorder	Hannah Jones	Sydney	Australia
PL005	Cognitive/Behavioral Disorders (including Autism)	The relationship between parental stress and mastery, forgiveness, and social support among parents of children with autism in a collectivistic and an individualistic society	Muhammad Mahajnah	Hadera	Israel
PL006	Critical Care	Prevalence of Prognostic Discordance for Infants in the Intensive Care Unit	Sarah Bernstein	Durham	United States
PL007	Demyelinating Disorders	Interim results from phase 2/3 (ALD-102) and phase 3 (ALD-104) studies of elivaldogene autotemcel (Lenti-D) gene therapy for the treatment of cerebral adrenoleukodystrophy	Florian Eichler	Boston	United States
PL008	Demyelinating Disorders	Development of the PedsQL™ Multiple Sclerosis Module items: Focus group and cognitive interviews	Cristina Gaudioso	St. Louis	United States
PL009	Demyelinating Disorders	Pediatric MOG antibody-associated syndromes: Description of a novel neuroimaging pattern	Sylvia Tenembaum	Buenos Aires	Argentina
PL010	Demyelinating Disorders	Use of disease-modifying therapies in paediatric relapsing remitting multiple sclerosis in the UK: A multi-centre retrospective study	Omar Abdel Mannan	London	United Kingdom
PL011	Epilepsy	Time to Onset of Cannabidiol (CBD) Treatment Effect and Resolution of Adverse Events in the Tuberous Sclerosis Complex (TSC) Phase 3 Randomized Controlled Trial (GWPCARE6)	Charuta Joshi	Aurora	United States
PL012	Epilepsy	Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Patients with Lennox Gastaut Syndrome (LGS): 3-Year Results of an Open-Label Extension (OLE) Trial (GWPCARE5)	Anup Patel	Columbus	United States
PL013	Epilepsy	Preventive antiepileptic treatment in infants with Tuberous Sclerosis Complex delays seizure onset and reduces epilepsy incidence and severity in a multi-center, randomized and observational EPISTOP trial	Katarzyna Kotulska	Warsaw	Poland
PL014	Epilepsy	Oligonucleotide STK-001 for the treatment of Dravet Syndrome: Cross-species pharmacology and efficacy in a mouse disease model	Barry Ticho	Bedford	United States
PL015	Epilepsy	Bridging the Childhood Epilepsy Treatment Gap in Africa (BRIDGE): A Protocol for a Cluster Randomized Clinical Trial of Task-Shifted Epilepsy Care in Three Northern Nigerian Cities	Edwin Trevathan	Nashville	United States
PL016	Epilepsy	Diagnostic and prognostic utility of outpatient short term video EEG records in children with seizures: experience from a tertiary care center in north India.	Prateek Panda	Rishikesh	India
PL017	Epilepsy	Epilepsy with Myoclonic Atonic Seizures (Doose Syndrome): A Severe Epileptic Encephalopathy with a Positive Outlook?	Katherine Nickels	Rochester	United States
PL018	Epilepsy	Electroclinical spectrum of childhood epilepsy secondary to neonatal hypoglycemic brain injury in a low resource setting: A 10 year experience	Bijoy Patra	Delhi	India
PL019	Epilepsy	Provider attitudes toward sexual and reproductive healthcare for young women with epilepsy and intellectual disabilities	Laura Kirkpatrick	Pittsburgh	United States
PL020	Epilepsy	Role of immunotherapy in children with new onset refractory status epilepticus (NORSE): Hit early and hit hard.	Harshkumar Patel	Ahmedabad	India
PL021	Epilepsy	Update on a sponsored no-cost epilepsy gene panel for seizure onset between 2–4 years of age: Results from 682 tests	Tiffany Pang	Novato	United States
PL022	Epilepsy	Management practices for West syndrome in South Asia: a survey study and meta-analysis	Priyanka Madaan	Chandigarh	India
PL023	Epilepsy	Hemodynamic responses to interictal epileptiforme discharges and clinical prognosis in childhood epilepsy with centrotemporal spikes	Ana Carolina Coan	Campinas	Brazil
PL024	Epilepsy	Perspectives on Preferred Practices for Rescue Therapies in Epilepsy: Gaps or Agreement?	Patricia Shafer	Wilmington	United States
PL025	Epilepsy	Medically intractable myoclonic epilepsy, intellectual disability, and dysmorphism in a teenage girl caused by a novel variant in NEXMIF	Isabella Herman	Houston	United States
PL026	Epilepsy	High dose diazepam treatment for Electrical Status Epilepticus in Sleep (ESES): Is it effective?	Carolina Gorodetsky	Toronto	Ontario
PL027	Epilepsy	Thalamocortical Loop Models as an Integrative Framework for Epileptiform Activity.	Andrew Knox	Madison	United States
PL028	Epilepsy	Efficacy of Combined Therapy of ACTH plus Vigabatrin compared to ACTH alone for treatment of Infantile Spasm- A Randomized controlled trail	Samsun Sumi	Dhaka	Bangladesh
PL029	Epilepsy	Thrombocytopenia in pediatric patients on concurrent cannabidiol and valproic acid	Nancy McNamara	Ann Arbor	United States
PL030	Epilepsy	Long-Term (2-Year) Safety and Efficacy of Adjunctive ZX008 (Fenfluramine Hydrochloride Oral Solution) for Dravet Syndrome: Interim Results of an Ongoing Open- Label Extension Study	Joseph Sullivan	San Francisco	United States
PL031	Epilepsy	Number Needed to Treat (NNT) With Fenfluramine to Achieve a Clinically Meaningful Reduction in Convulsive Seizure Frequency in Patients With Dravet Syndrome	Joseph Sullivan	San Francisco	United States
PL032	Epilepsy	POTENTIAL MECHANISMS OF SUDEP IN MOUSE MODEL OF ALTERNATING HEMIPLEGIA OF CHILDHOOD	Courtney Elliott	Chapel Hill	United States
PL033	Epilepsy	Improving folate supplementation counseling for adolescent females with epilepsy.	Sara Fridinger	Philadelphia	United States
PL034	Epilepsy	Worldwide short course education programmes in paediatric epilepsies – improving knowledge and changing attitudes and practice.	Alison Gifford	Dundee	United Kingdom
PL035	Epilepsy	Neuroimaging for Non-Index Seizures in Pediatric Emergency Rooms	Emma Mazzio	Denver	United States
PL036	Epilepsy	Decision-Making for Infants with Neurologic Conditions	Charlotte Gerrity	Durham	United States
PL037	Epilepsy	The expressions of microRNAs in febrile seizure	Kursat Carman	Eskisehir	Turkey
PL038	Genetics	Episodic hemiplegia secondary to channelopathies: clinical spectrum and genotype- phenotype correlations	Daniel Calame	Houston	United States
PL039	Genetics	Variability in diagnostic yield of exome sequencing by clinical phenotype: Review of 977 cases from a single center	Cameron Crockett	St. Louis	United States
PL040	Genetics	Pediatric 50K (P50K) Heredigene Project: Whole Genome Sequencing Initiative for 50,000 Children: Integrating Genomic Testing and Data with Longitudinal Pediatric Clinical Outcomes and Treatments in an Integrated Healthcare System	Josh Bonkowsky	Salt Lake City	United States
PL041	Genetics	Human Genetic Risk and Protective Factors In Congenital Zika Syndrome	Youssef Kousa	Washington	United States
PL042	Genetics	Characterization of PTEN-associated cortical malformations and associated clinical phenotype	Diane Shao	Boston	United States
PL043	Genetics	Diagnostic yield of genetic testing in infants with congenital hypotonia	Sonal Sharma	Kansas City	United States
PL044	Infections/Neuroimmunology	Common autoantigen identified in a cohort of ROHHAD-NET patients, supporting ROHHAD as a novel paraneoplastic neurological disorder	Caleigh Mandel-Brehm	San Francisco	United States
PL045	Infections/Neuroimmunology	Think AFM: many patients with acute flaccid myelitis are misdiagnosed	Leslie Hayes	Boston	United States
PL046	Infections/Neuroimmunology	Validity of the clinical diagnostic criteria for anti-N-methyl-D-aspartate receptor encephalitis in Japanese pediatric patients	Hiroya Nishida	Tokyo	Japan
PL047	Infections/Neuroimmunology	Comparison of Seizure Type and EEG findings in Autoimmune Encephalitis: A Multicenter Sample	Annie Hong	New Hyde Park	United States
PL048	Infections/Neuroimmunology	Clinico-radiological profile of children with acute necrotizing encephalopathy of childhood(ANEC) associated with dengue fever: A case series	Harshkumar Patel	Ahmedabad	India
PL049	Infections/Neuroimmunology	GAD65 Antibody Encephalitis presenting as treatment resistant temporal lobe epilepsy and peripheral neuropathy in a pediatric patient	Maryam Nabavi Nouri	London	Ontario
PL050	Infections/Neuroimmunology	Acute Encephalitis in the Pediatric Population of Western Pennsylvania	Meghan Mack	Pittsburgh	United States
PL051	Movement Disorders (including Cerebral Palsy)	The effect of intrathecal baclofen in dyskinetic cerebral palsy (IDYS trial): a multi-centre, randomised, double-blind, placebo-controlled trial	Laura Bonouvrie	Amsterdam	Netherlands
PL052	Movement Disorders (including Cerebral Palsy)	Stereotypies have lower burden of comorbidity compared to tics	Shannon Dean	Baltimore	United States
PL053	Movement Disorders (including Cerebral Palsy)	Anxiety symptoms in youth with and without tic disorders	Jennifer Vermilion	Rochester	United States
PL054	Movement Disorders (including Cerebral Palsy)	Improved Motor Function in Children With AADC Deficiency Treated with Eladocagene Exuparvovec (PTC-AADC): Interim Findings from a Phase 2 Trial	Yin-Hsiu Chien	Taipei City	Taiwan
PL055	Movement Disorders (including Cerebral Palsy)	High-throughput Screen For Small Molecules That Modulate Protein Trafficking In Adaptor Protein Complex 4 (AP-4) Associated Hereditary Spastic Paraplegia	Darius Ebrahimi-Fakhari	Boston	United States
PL056	Movement Disorders (including Cerebral Palsy)	Improved Motor Function in Children With AADC Deficiency Treated With Eladocagene Exuparvovec (PTC-AADC): Compassionate Use Study	Paul Wuh-Liang Hwu	Taipei City	Taiwan
PL057	Neonatal & Fetal Neurology	Lateralized neonatal EEG response to maternal voice exposure as a predictor of language outcome	Renee Shellhaas	Ann Arbor	United States
PL058	Neonatal & Fetal Neurology	Duration of Anti-seizure Medication Treatment and 2-Year Outcome After Acute Symptomatic Neonatal Seizures – a Neonatal Seizure Registry study	Hannah Glass	San Francisco	United States
PL059	Neonatal & Fetal Neurology	Short-Term Seizure Recurrence In Neonates With Acute Symptomatic Seizures: Early Vs Late Discontinuation Of Anti-epileptic drugs: A Randomized, Controlled, Non-Inferiority Trial	Ramesh Konanki	Hyderabad	India
PL060	Neonatal & Fetal Neurology	Effect of therapeutic hypothermia and pattern of injury on neurodevelopmental outcomes at 1-2 years in a prospective cohort of neonatal encephalopathy	Ashley Bach	San Francisco	United States
PL061	Neonatal & Fetal Neurology	Placental abnormalities in a large cohort of neonatal hypoxic-ischemic encephalopathy (HIE)	Amy Goodman	San Francisco	United States
PL062	Neonatal & Fetal Neurology	Advanced genetic analysis in fetuses and term neonates with idiopathic cerebral hemorrhage	Moran Hausman-Kedem	Tel-Aviv	Israel
PL063	Neonatal & Fetal Neurology	Hyperglycemia in term neonatal encephalopathy associated with increased risk for neonatal seizures	Carlos Salazar	Toronto	Ontario
PL064	Neurometabolic Disorders	Persistent treatment effect of cerliponase alfa in children with CLN2 disease: A >4 year update from an ongoing multicenter extension study	Angela Schulz	Hamburg	Germany
PL065	Neurometabolic Disorders	Reduction of Rate of Severity Increment in a Cohort of Patients with Niemann-Pick Type C1 (NPC1) Treated Long-Term With Intrathecal Adrabetadex	Elizabeth Berry-Kravis	Chicago	United States
PL066	Neurometabolic Disorders	Development of the “Hamburg Best Practice Guidelines for intracerebroventricular (ICV)- enzyme replacement therapy (ERT) in CLN2 Disease” based on 5 years treatment experience in 48 patients	Christoph Schwering	Hamburg	Germany
PL067	Neurometabolic Disorders	Single-dose AAV9-CLN6 gene transfer stabilizes motor and language function in CLN6- type Batten disease: interim results from the first clinical gene therapy trial	Emily de los Reyes	Columbus	United States
PL068	Neuromuscular Disorders	Increased intracranial pressure in pediatric patients with Spinal Muscular Atrophy receiving nusinersen via lumbar puncture	Stephanie Acord	Fortworth	United States
PL069	Neuromuscular Disorders	Ataluren delays loss of ambulation and decline in pulmonary function in patients with nmDMD	Craig McDonald	Sacramento	United States
PL070	Neuromuscular Disorders	Onasemnogene Abeparvovec-xioi Gene Therapy for Spinal Muscular Atrophy Type 1 (SMA1): Phase 3 Study Clinical Update (STR1VE-EU)	Eugenio Mercuri	Rome	Italy
PL071	Neuromuscular Disorders	Nusinersen in Infantile-onset Spinal Muscular Atrophy: Results from Longer-term Treatment from the Open-label SHINE Extension Study	Boris Kandinov	Cambridge	United States
PL072	Neuromuscular Disorders	Nusinersen in advanced-stage patients with spinal muscular atrophy type1.	Katarzyna Kotulska	Warsaw	Poland
PL073	Neuromuscular Disorders	One-Time Administration of AVXS-101 IT for Spinal Muscular Atrophy: Phase 1/2 Study (STRONG)	Richard Finkel	Orlando	United States
PL074	Neuromuscular Disorders	Longer-term Nusinersen Treatment According to Age at First Dose: Results From the SHINE Study in Later-onset Spinal Muscular Atrophy (SMA)	Basil Darras	Boston	United States
PL075	Neuromuscular Disorders	Pulmonary function in non-ambulatory patients with nmDMD: Strategic Targeting of Registries and International Database of Excellence (STRIDE) Registry and CINRG DNHS matched cohort analysis	Andrés Nascimento Osorio	Barcelona	Spain
PL076	Neuromuscular Disorders	Beyond the Muscle: The Expanding Mutational and Phenotypic Spectrum of Disease Due to Mutations in the MICU1 gene (mitochondrial calcium uptake 1)	Shanawaz Hussain	Leeds	United Kingdom
PL077	Neuromuscular Disorders	Onasemnogene Abeparvovec-xioi Gene Therapy in Presymptomatic Spinal Muscular Atrophy: SPR1NT Study Update	Kevin Strauss	Strasburg	United States
PL078	Neuromuscular Disorders	Nusinersen Effect in Infants Who Initiate Treatment in a Presymptomatic Stage of SMA: NURTURE Results	Darryl De Vivo	New York	United States
PL079	Neuromuscular Disorders	Long-Term Follow-Up of Onasemnogene Abeparvovec-xioi Gene Therapy in Spinal Muscular Atrophy Type 1 (SMA1)	Jerry Mendell	Columbus	United States
PL080	Neuromuscular Disorders	Georgia state SMA newborn screening (NBS) pilot: clinical outcomes and way forward	Kathryn Elkins	Atlanta	United States
PL081	Neuromuscular Disorders	Intravenous (IV) Onasemnogene Abeparvovec-xioi Clinical Development Programs in Spinal Muscular Atrophy (SMA): Integrated Safety Report	Deepa Chand	Bannockburn	United States
PL082	Neuromuscular Disorders	Edasalonexent Treatment in Young Boys with Duchenne Muscular Dystrophy is Associated with Age-Normative Growth and Normal Adrenal Function	Erika Finanger	Portland	United States
PL083	Neuromuscular Disorders	Systemic Gene Transfer with rAAVrh74.MHCK7.SGCB Increased β-sarcoglycan Expression in Patients with Limb Girdle Muscular Dystrophy Type 2E (LGMD2E)	Louise Rodino-Klapac	Cambridge	United States
PL084	Neuromuscular Disorders	Systemic Gene Transfer with rAAVrh74.MHCK7.micro-dystrophin in Patients with Duchenne Muscular Dystrophy	Jerry Mendell	Columbus	United States
PL085	Neurorehabilitation	Development and Evaluation of a low-cost working memory intervention kit for cognitive deficits in children with epilepsy: a pilot study	Aakanksha Anand	New Delhi	India
PL086	Neurorehabilitation	Efficacy of abobotulinumtoxinA in reducing upper-limb spasticity in children with cerebral palsy: Results from a Phase 3, pivotal study	Ann Tilton	New Orleans	United States
PL087	Neuroscience	Dysfunction of D2 dopamine receptor neurons underlies select manic-like behaviors in SHANK3 overexpressing mice	J. Holder, Jr.	Houston	United States
PL088	Rare Diseases	The natural history of fatty acid hydroxylase-associated neurodegeneration (FAHN).	Sunita Venkateswaran	Ottawa	Ontario
PL089	Rare Diseases	Efficacy and safety of arimoclomol in patients with Niemann Pick Type C: Results from a double-blind, randomised placebo-controlled trial with a novel treatment	Marc Patterson	Rochester	United States
PL090	Stroke (including other Vascular Disorders)	Harnessing Multimodal Neuroimaging to Predict Higher-Order Language Outcome Post Neonatal Stroke: An In Vivo Model of Neuroplasticity	Zahra Emami	Toronto	Ontario
PL091	Stroke (including other Vascular Disorders)	Robotic sensorimotor assessment of children with perinatal stroke and hemiparesis following intensive motor learning and neuromodulation	Lauran Cole	Calgary	Alberta
PL092	Stroke (including other Vascular Disorders)	Regional thalamic dysrhythmia and connectivity abnormalities relate to motor performance in children with perinatal stroke	Anton Rogachov	Toronto	Canada
PL093	Stroke (including other Vascular Disorders)	Posterior Choroidal Artery Collaterals Predict Ischemic Event Recurrence and Response to Revascularization Surgery in Childhood Moyamoya	Matsanga Leyila Kaseka	Toronto	Ontario
PL094	Stroke (including other Vascular Disorders)	Perinatal infections: an important etiological risk factor for Mineralizing angiopathy in children	Mahesh Kamate	Belagavi	India
PL095	Stroke (including other Vascular Disorders)	Intracranial and extracranial vascular stenosis as risk factors for stroke in sickle cell disease	Alyssa Schlotman	Nashville	United States
PL096	Stroke (including other Vascular Disorders)	Cerebral venous sinus thrombosis in infants after surgery for congenital heart disease	Dana Harrar	Washington	United States
PL097	Teaching of Child Neurology	Quality Improvement Measures in an Academic Pediatric Neurology Outpatient Practice	Stephanie Enner	Queens	United States
PL098	Teaching of Child Neurology	Adoption of Telemedicine within Pediatric Neurology of the MGH Healthcare System before and during the COVID-19 Pandemic	Albert Misko	Boston	United States
PL099	Translational/Experimental Therapeutics	Transpher A, an open-label, multicenter, single-dose, dose-escalation, Phase 1/2 Clinical Trial of gene transfer of ABO-102 in Sanfilippo Syndrome type A (Mucopolysaccharidosis IIIA): Safety, tolerability, biopotency and neurocognitive data	Kevin Flanigan	Columbus	United States
PL100	Trauma	Cerebral blood flow predicts outcome in children with persistent post-concussion syndrome	Karen Barlow	Brisbane	Australia
Platform	Section	Title	Presenter	City	Country

Log in with ( Sign Up ? )

or post as a guest